Notícias e Atividades da Agios Pharmaceuticals

A Agios Pharmaceuticals pertence à Sagard Holdings. Sagard Holdings tem presença direta em 4 países.

Sagard Holdings possui 11 subsidiárias incluindo Acheel, Achieve e ADIT.

Eles estão dentro:

• Seguros25%
• Serviços Financeiros17%
• Outro58%

Veja o organograma con seus 21 executivos principais

Biografias mais buscadas da Agios Pharmaceuticals

• Brian Goff, Chief Executive Officer and Director
• Maykin Ho, Director
• Catherine Owen, Director

Recentes movimentos de executivos em Sagard Holdings

• Kris Hansen, Chief Technology Officer, deixou a Companhia  (Notícia publicada em 5 de janeiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Agios Pharmaceuticals.

Sagard Holdings possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Agios Pharmaceuticals

• Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 | Agios Pharmaceuticals, Inc.
• Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia | Agios Pharmaceuticals, Inc.
• Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients | Agios Pharmaceuticals, Inc.
• Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs | Agios Pharmaceuticals, Inc.
• Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 | Agios Pharmaceuticals, Inc.
• Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 | Agios Pharmaceuticals, Inc.
• Agios Reports Business Highlights and Second Quarter 2020 Financial Results | Agios Pharmaceuticals, Inc.
• Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020 | Agios Pharmaceuticals, Inc.
• Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 | Agios Pharmaceuticals, Inc.
• Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia | Agios Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Agios Pharmaceuticals

• Agios Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Agios Pharmaceuticals na LinkedIn, X (Twitter) e YouTube